Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
KYMR reported multiple Rule 144 notices of proposed sales of Common Stock by affiliated funds and an individual associated with Atlas Venture between April and June 2026. The filings list individual transactions such as 243,976 shares on 06/22/2026 (Atlas Venture Fund X) and 100,928 shares on 06/18/2026 (Atlas Venture Fund X).
The notices present per‑transaction share counts and cash amounts for private placement resale activity and insider/affiliate dispositions; amounts are reported on specific trade dates rather than as an aggregated total.
KYMR insiders and affiliated holders submitted a Form 144 notice for proposed resales of Common Stock by selling holders, including multiple transactions by Atlas Venture funds and an individual, Bruce Booth. The excerpt lists specific sale dates, share counts, and gross proceeds for transactions in April–June 2026.
The filings show examples such as Atlas Venture Fund X, L.P. selling 243,976 shares on 06/22/2026 for $24,182,608.35 and Atlas Venture Opportunity Fund I, L.P. selling 34,152 shares on 06/22/2026 for $3,385,105.26. Multiple smaller and larger dispositions by the same holders appear across 04/15/2026 through 06/23/2026.
Kymera Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 24, 2026. Shareholders elected four Class III directors — Bruce Booth, Nello Mainolfi, John Maraganore and Elena Ridloff — each to serve three-year terms ending at the 2029 annual meeting.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 74,903,687 votes for and 2,462,732 against. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 79,043,801 votes for and minimal opposition.
KYMR reported affiliate sale notices under Rule 144 listing multiple proposed dispositions of Common Stock by Atlas Venture funds and an individual, with trades dated in April and June 2026. Examples include Atlas Venture Fund X, L.P. selling 243,976 shares for $24,182,608.35 on 06/22/2026 and Bruce Booth selling 11,741 shares for $1,056,443.24 on 06/17/2026.
KYMR (issuer) submitted a Form 144 notice reporting proposed sales of Common Stock by affiliated holders. The filing lists multiple past and proposed dispositions by Atlas Venture funds and individuals, including large block sales on 06/22/2026 and earlier April–June 2026 transactions.
Kymera Therapeutics, Inc. reported insider-related open-market sales of its common stock by Atlas Venture funds associated with director Bruce Booth. On June 22, 2026, entities reported aggregate sales of 31,798 shares at weighted average prices around $103–$104 per share under a pre-established Rule 10b5-1 trading plan.
The shares are held directly by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest. After these transactions, related entities reported holdings of 613,762 and 3,472,340 Kymera shares, indicating they continue to hold substantial positions.
Kymera Therapeutics director‑associated entities reported sizeable June stock sales alongside an option exercise. Across June 17–22, entities linked to Bruce Booth sold a net 478,198 shares of Kymera common stock in open‑market transactions at prices generally around the low‑ to low‑$100 range.
Most shares are held directly by Atlas Venture Fund X and Atlas Venture Opportunity Fund I; Booth is a member of their general partners and disclaims Section 16 beneficial ownership beyond any pecuniary interest. On June 17, he exercised stock options for 11,741 shares at $20.00 per share and sold all those shares at a weighted‑average price of $89.98, leaving no direct common‑stock holdings but 28,127 fully vested options outstanding that expire on August 19, 2030. Several sales were executed under Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options for 2,500 shares of common stock at $21.05 per share and on the same day sold 2,500 shares in an open-market transaction at $99.00 per share. Following these transactions, he directly holds 50,195.438 shares of common stock. The trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.
KYMR reported officer/affiliate sales disclosed on Form 144. The excerpt lists multiple sales by Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P. and Bruce Booth between 04/14/2026 and 06/18/2026, showing individual transactions with share counts and cash amounts.
The filings identify the security as Common Stock and note prior private placement issuance on 03/11/2020. The excerpt provides per-transaction share counts (for example, 100,928 shares on 06/18/2026) and corresponding cash amounts, but does not state aggregate proceeds to the issuer.
KYMR filed Form 144 reporting the resale of 243,976 shares of Common Stock. The notice lists multiple sales by Atlas Venture funds and affiliated individuals on 04/15/2026, 04/22/2026, 06/17/2026, and 06/18/2026, with per‑trade share counts and cash proceeds shown.
The entries identify the sales as resale transactions tied to a prior Private Placement (03/11/2020) and show cash proceeds for each trade; the filings are routine resale notices under Section 144.